COYA שולי רווחיות גולמית Coya

Coya Therapeutics, Inc. (COYA) utilizes bioinformatics and automation to discover treatments for neurodegeneration. The gross margin as a percentage of revenue on the GURU.Markets daily price chart reflects a trend where the value remains at 99.70. The asset's capitalization depends on the success of clinical phases, ignoring macroeconomics, although fierce competition with tech giants in the neuroimmunology niche creates significant risks for the company.
פילוחי מדדים פיננסיים ומדדי שוק עבור Coya Therapeutics, Inc. (COYA)

This indicator measures the portion of revenue free from direct production costs, allowing investors to track operational efficiency between quarterly reports. For Coya Therapeutics, Inc. (COYA), which is protected by FDA barriers, the current gross margin serves as a marker for the capitalization of intellectual property and patent purity, where increasing values confirm the high added value of innovative therapy compared to development costs.